83 Gene Therapy (AAV / Viral Vector) CRO and CDMO vendors

What does it take to develop and manufacture a Gene Therapy (AAV / Viral Vector) drug?

Gene therapy stretches a development team across two very different worlds. The early science looks like any biologics program: pick a transgene, choose or engineer a capsid serotype that reaches the target tissue, design the expression cassette and promoter, then prove in preclinical models that the construct does what you claim without lighting up the immune system. The hard, expensive reality lands later, in CMC. The vector you make is not a small molecule with a clean structure; it is a population of viral particles, some full of your genome and some empty, and your process and your analytics define the product as much as the sequence does. That is why so many gene therapy programs that read well on biology stall at manufacturing.

A typical program needs a CRO for the discovery and preclinical work (capsid screening, biodistribution and shedding studies, immunogenicity and GLP toxicology in a relevant species), then a CDMO for process development and GMP supply. The manufacturing side is where the specialist gap is widest. Upstream, you are running either a transient transfection process (three or four plasmids into HEK293 cells, which means you also need GMP plasmid DNA) or a producer or packaging cell line. Downstream, you are clarifying, concentrating, and polishing with affinity chromatography and tangential flow filtration, then trying to separate full capsids from empty ones, often by anion exchange or gradient ultracentrifugation. Each step bleeds yield, and AAV yields are low to begin with, so process choices made early ripple straight into cost of goods and how many patients a batch can dose.

The analytics are the part generalists underestimate. You need vector genome titer (qPCR or ddPCR), capsid titer, the full-to-empty ratio, infectivity and potency assays that tie back to mechanism, residual host cell DNA and protein, residual plasmid and helper, replication-competent virus testing, and aggregation. A CDMO that has built and qualified these assays for AAV, and ideally has a platform process across serotypes, is in a different category from a contract biologics shop that lists gene therapy on a capabilities page. Specialist viral vector CDMOs differ from generalists in three concrete ways: a real platform process they can adapt rather than invent from scratch, a qualified AAV-specific analytical panel, and people who have actually carried a vector through a regulatory filing and the FDA potency and comparability questions that come with it.

How do you choose a CRO or CDMO for Gene Therapy (AAV / Viral Vector)?

The instinct to chase the biggest name is usually wrong here, because capacity in this field is genuinely scarce and a marquee CDMO booked solid for eighteen months can be worse for your program than a focused vector house with an open suite. Anchor the decision on demonstrated AAV experience with your serotype and your scale, not a logo or a glossy capabilities deck. Score two or three vendors against the same written scope, and weight the manufacturing and analytics evidence heavily, since that is where gene therapy programs actually fail.

Use the checklist below when you compare vendors. Treat anything a vendor cannot answer with specifics as a flag, not a detail to sort out later.

• Relevant platform and track record: ask which AAV serotypes they have produced, whether they run a transient transfection or stable producer cell line process, and how many client vectors have reached IND or BLA. A reusable platform process beats a bespoke one invented for your project.
• GxP and analytical capability for this modality: confirm GMP suites at the right grade, a qualified AAV analytics panel (vector genome titer, full-to-empty ratio, infectivity and potency, residual host cell DNA and protein, replication-competent virus), and whether potency and identity assays are developed in-house or outsourced.
• Plasmid and raw material supply: AAV needs GMP plasmid DNA, and plasmid lead times can dominate your timeline. Check whether the CDMO makes plasmid in-house or relies on a third party, and whether helper and packaging components are secured.
• Capacity and scale: get real suite availability and a realistic slot, the bioreactor scale they can deliver (from 50L suspension up to 200L or 500L and beyond), and an honest read on yield per batch at your serotype, since that decides how many patients a lot can dose.
• Regulatory experience: confirm they have supported INDs and ideally a BLA, can produce a potency and comparability story the FDA or EMA will accept, and have lived through real agency questions on empty capsids, RCV, and process changes.
• IP and confidentiality: settle ownership of process and analytical know-how and any platform-derived improvements in writing, watch for proprietary cell lines or capsids that carry royalty or freedom-to-operate strings, and get a CDA in place before disclosing your construct.